Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Receives Notice of Allowance on Patent Application Covering Delivery Tech


Arrowhead Research this week announced that it has received a notice of allowance from the US Patent and Trademark Office that it will be granted a patent on an application covering its dynamic polyconjugate delivery technology.

The patent application, No. 20120165393, is entitled “Peptide-based In Vivo siRNA Delivery System” and claims the targeted delivery of RNAi oligos to hepatocytes when administered along with co-targeted melittin delivery peptides.

The peptides, the patent application indicates, enable cellular membrane penetration.

The patent application, Arrowhead noted, specifically covers the delivery technology being used with the company’s preclinical hepatitis B therapy ARC-520, which is slated to enter phase I testing this year (GSN 2/14/2013).